Multifunctional platinum‐based nanoparticles for biomedical applications
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Platinum‐based anticancer drugs play a central role in current cancer therapy. However, their applicability and efficacy are limited by drug resistance and adverse effects. Nanocarrier‐based platinum drug delivery systems are promising alternatives to circumvent the disadvantages of bare platinum drugs. The various properties of nanoparticle chemistry allow for the trend toward multiple functionality. Nanoparticles preferentially accumulate at the tumor site through passive targeting, and the attachment of tumor targeting moieties further enhances their tumor‐specific localization as well as tumor cell uptake. The introduction of stimuli‐responsive groups into drug delivery systems can further achieve spatially and temporally controlled drug release in response to specific stimuli. Combination therapy strategies have been used to promote synergetic efficacy and overcome the resistance of platinum drugs. The tumor‐localized drug delivery strategies exhibit benefits for preventing local tumor recurrence. In addition, the combination of platinum drugs and imaging agents in one unity allows the cancer diagnostics for real‐time monitoring the distribution of drug‐loaded nanoparticles inside the body and tumor. This review discusses recent scientific advances in multifunctional nanoparticle formulations of platinum drugs, and these designs exhibit new potential of multifunctional nanoparticles for delivering platinum‐based anticancer drugs.WIREs Nanomed Nanobiotechnol 2017, 9:e1410. doi: 10.1002/wnan.1410 This article is categorized under:Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
He, C., Lu, K., Liu, D., & Lin, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4098862 · Cited by 885
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Studies on thermoresponsive polymers: Phase behaviour, drug delivery and biomedical applications
Gandhi, A., Paul, A., Sen, S. O., & Sen, K. K. (2015) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.08.010 · Cited by 506
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390
Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303958110 · Cited by 340
Lipoplatin Formulation Review Article
Stathopoulos, G. P., & Boulikas, T. (2012) · Journal of Drug Delivery · doi:10.1155/2012/581363 · Cited by 224
Folate-decorated nanogels for targeted therapy of ovarian cancer
Nukolova, N. V., Oberoi, H. S., Cohen, S. M., Kabanov, A. V., & Bronich, T. K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.006 · Cited by 223
Jain, A., Jain, S. K., Ganesh, N., Barve, J., & Beg, A. M. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.03.002 · Cited by 214
Doles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011409107 · Cited by 190
Cai, L., Xu, G., Shi, C., Guo, D., Wang, X., & Luo, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.044 · Cited by 151
Ahn, J., Miura, Y., Yamada, N., Chida, T., Liu, X., Kim, A., Sato, R., Tsumura, R., Koga, Y., Yasunaga, M., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.069 · Cited by 147
He, Z., Huang, J., Xu, Y., Zhang, X., Teng, Y., Huang, C., Wu, Y., Zhang, X., Zhang, H., & Sun, W. (2015) · Oncotarget · doi:10.18632/oncotarget.6243 · Cited by 112
Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer
Desale, S. S., Cohen, S. M., Zhao, Y., Kabanov, A. V., & Bronich, T. K. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.026 · Cited by 110
Babu, A., Wang, Q., Muralidharan, R., Shanker, M., Munshi, A., & Ramesh, R. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500259e · Cited by 94
LHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer
Nukolova, N. V., Oberoi, H. S., Zhao, Y., Chekhonin, V. P., Kabanov, A. V., & Bronich, T. K. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4003688 · Cited by 63
Targeted delivery of platinum-taxane combination therapy in ovarian cancer
Desale, S. S., Soni, K. S., Romanova, S., Cohen, S. M., & Bronich, T. K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.007 · Cited by 61
Huang, R., Sun, Y., Zhang, X.-Y., Sun, B.-W., Wang, Q.-C., & Zhu, J. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.05.013 · Cited by 21
Cited by
Platinum-based drugs for cancer therapy and anti-tumor strategies
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022) · Theranostics · doi:10.7150/thno.69424 · Cited by 1,018
Wang, L., Guan, R., Xie, L., Liao, X., Xiong, K., Rees, T. W., Chen, Y., Ji, L., & Chao, H. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202013987 · Cited by 289
Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy
Liu, P., Hao, L., Liu, M., & Hu, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1161472 · Cited by 58
“This complex can then be cleared by MRPs (Kilari et al., 2016; Cheng and Liu, 2017).”
BackgroundYusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
“Also, the tumour-localised drug delivery strategies exhibit benefits for preventing local tumour recurrence [141].”
Huang, H., Shi, H., Liu, J., Min, Y., Wang, Y., Wang, A. Z., Wang, J., & Liu, Y. (2017) · Chemical Communications · doi:10.1039/c6cc08146k · Cited by 34
Self-citation
Metadata
- Authors
- Cheng, Q., & Liu, Y.
- Venue
- WIREs Nanomedicine and Nanobiotechnology
- Publisher
- Wiley
- Published
- 2016-04-20
- Volume
- 9
- Issue
- 2
- ISSN
- 1939-0041 (ISSN-L)
- 1939-5116
- OpenAlex
- W2339851538
- Cited by
- 76
- References
- 22
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.